The class I metabotropic glutamate receptor antagonist, AIDA, improves short-term and impairs long-term memory in a spatial task for rats

Duration of aversive memory in zebrafish after a single shock

Studies on memory consolidation and reconsolidation, memory loss, and the associated biochemical mechanisms have garnered interest in the past decades due to knowledge of memory performance-affecting factors such as stress, emotions, sleep, age, several neurological diseases, drugs, and chemical pollutants. Memory research has been using animal models, with increased interest in the zebrafish model. This freshwater fish species shows a wide range of behaviors relevant to memory research such as social behavior, aggression, and predator avoidance; however, few studies have investigated the duration of long-term memory. Hence, we designed an experiment to test memory duration by exposing zebrafish to avoidance conditioning using electroshock as the aversive stimulus. Zebrafish were trained to avoid the black side of a black-and-white tank and subsequently tested for aversive memory at 24 h, 48 h, 72 h, 96 h, 168 h, and 240 h. At the 72 h-interval, another zebrafish group was trained and exposed to MK-801(NMDAr antagonist) and then tested. The fish retained memories of the task and avoided the black side of the tank for up to 7 days. At 10 days post-training, the animals could no longer retrieve the aversive memory. Zebrafish treated with MK-801 did not retrieve memory. Knowledge of memory and of long-term memory duration is crucial for optimizing the zebrafish model for use in research investigating cognitive impairments such as memory loss and its ramifications. Additionally, identifying a long-term aversive memory lasting up to 7 days in zebrafish enables further research into the neuronal changes underlying this persistence. Such in-depth investigation could bring valuable insights into memory mechanisms and facilitate targeted interventions for memory-related conditions.

Revisiting and revising memory consolidation: Personal reflections on the research legacy of Ivan Izquierdo

Two important themes in Ivan Izquierdo's research each offered both answers and questions about the topic of memory formation and maintenance. The first theme provided evidence supporting the view that short- and long-term memory were distinct processes and could be selectively modulated by several treatments, with some affecting only short-term, others only affecting long-term memory, and still others affecting both. Over many years, Izquierdo's laboratory documented molecular responses across time after training obtaining results that showed differences as well as similarities in the biochemical changes during the first 1-2 hours and the next 4-6 hours after training, i.e., during the transition from short- to long-term memory. This work clarified the biological underpinnings of the memory processes. The second theme described waves of susceptibility of memory to enhancing and impairing treatments after time, a biphasic profile that contrasted with earlier monotonic decreases in the efficacy of memory modulating treatments as a function of time between training and treatment. Remarkably, these waves of susceptibility to modification were accompanied by biphasic changes in molecular measures at similar times after training. Remarkably, some of the molecular players exhibited persistent changes after training, with increases in levels lasting days following the training experience. These persistent molecular changes may reveal a biological basis for the dynamic nature of memories seen long after the initial memory is consolidated.

International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors

Metabotropic glutamate (mGlu) receptors respond to glutamate, the major excitatory neurotransmitter in the mammalian brain, mediating a modulatory role that is critical for higher-order brain functions such as learning and memory. Since the first mGlu receptor was cloned in 1992, eight subtypes have been identified along with many isoforms and splice variants. The mGlu receptors are transmembrane-spanning proteins belonging to the class C G protein-coupled receptor family and represent attractive targets for a multitude of central nervous system disorders. Concerted drug discovery efforts over the past three decades have yielded a wealth of pharmacological tools including subtype-selective agents that competitively block or mimic the actions of glutamate or act allosterically via distinct sites to enhance or inhibit receptor activity. Herein, we review the physiologic and pathophysiological roles for individual mGlu receptor subtypes including the pleiotropic nature of intracellular signal transduction arising from each. We provide a comprehensive analysis of the in vitro and in vivo pharmacological properties of prototypical and commercially available orthosteric agonists and antagonists as well as allosteric modulators, including ligands that have entered clinical trials. Finally, we highlight emerging areas of research that hold promise to facilitate rational design of highly selective mGlu receptor-targeting therapeutics in the future. SIGNIFICANCE STATEMENT: The metabotropic glutamate receptors are attractive therapeutic targets for a range of psychiatric and neurological disorders. Over the past three decades, intense discovery efforts have yielded diverse pharmacological tools acting either competitively or allosterically, which have enabled dissection of fundamental biological process modulated by metabotropic glutamate receptors and established proof of concept for many therapeutic indications. We review metabotropic glutamate receptor molecular pharmacology and highlight emerging areas that are offering new avenues to selectively modulate neurotransmission.

mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?

Modulation of the mGlu1 receptor was repeatedly shown to inhibit various phenomena associated with exposure to abused drugs. Efficacy in preclinical models was observed with both positive and negative allosteric modulators (PAMs and NAMs, respectively) using essentially non-overlapping sets of experimental methods. Taken together, these data indicate that the mGlu1 receptor certainly plays a significant role in the plasticity triggered by the exposure to abused drugs and is involved in the maintenance of drug-seeking and drug-taking behaviors. Understanding whether modulation of the mGlu1 receptor activity can also affect drug-seeking and drug-taking in humans could have a significant impact on the future development of medications in this field. We argue that the mGlu1 receptor NAMs have a significant value as potential tools for human experimental pharmacology that could help to validate methods used in preclinical research. Compared with the PAMs, the mGlu1 receptor NAMs appear to be better candidates for this role due to the following: (1) a number of highly potent, selective, and chemically diverse mGlu1 receptor NAMs to choose from; (2) availability of high-quality PET ligands to monitor target exposure; and (3) a rich pharmacological profile with a number of effects that can complement anti-addictive action (e.g., anxiolytic/antidepressant) and may also serve as additional pharmacodynamic readouts during the preclinical-to-clinical translation. We believe that the mGlu1 receptor NAMs have a significant value as potential tools for human experimental pharmacology that could help to validate methods used in preclinical research.

Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness

Metabotropic glutamate mGlu(1) receptors play a modulatory role in the nervous system. They enhance cell excitability, modulate synaptic neurotransmission and are involved in synaptic plasticity. During the last 10 years, several selective metabotropic glutamate mGlu(1) receptor competitive antagonists and potentiators have been discovered. These pharmacological tools, together with early and later work in metabotropic glutamate mGlu(1) receptor mutant mice have allowed studying the role of the receptor in various aspects of psychiatric illnesses such as anxiety, depression and schizophrenia. We here review the data on selective metabotropic glutamate mGlu(1) receptor antagonists in support of their potential as anxiolytic and antidepressant treatments. We propose a rationale for the development of metabotropic glutamate mGlu(1) receptor positive allosteric modulators for the treatment of schizophrenia. Potential side effects of blockade and activation of metabotropic glutamate mGlu(1) receptors are addressed, with special focus on the differential effects of metabotropic glutamate mGlu(1) receptor antagonists in cognition models with positive reinforcement versus those that use aversive learning procedures. Further development of negative allosteric modulators and more drug-like positive allosteric modulators will be required in order to decipher the therapeutic efficacy and safety margin of these compounds in the clinic.

Effect of the class I metabotropic glutamate receptor antagonist AIDA on certain behaviours in rats with experimental chronic hyperammonemia

PURPOSE

This study examines possible interactions between behavioral effects and mGluR1 (class I metabotropic glutamate receptor) by injecting AIDA [(RS)-1-aminoindan-1,5-dicarboxylic acid] in rats with experimental chronic hyperammonemia (chHA).

MATERIAL/METHODS

The effects of mGluR1 antagonist on some behaviors were tested in control groups of rats and in rats with chHA. Experimental chHA was induced by intraperitoneal injection of ammonium acetate (12 mmol/kg) for five consecutive days. We used the following behavioural tests: the open field test, the passive avoidance test and the elevated "plus" maze.

RESULTS

In control rats AIDA administered intracerebroventricularly (i.c.v.) at the dose 100 nmol decreased the number of crossings and bar approaches in the open field test and impaired acquisition and recall in the passive avoidance situation. ChHA significantly inhibited locomotor and exploratory activity and profoundly impaired acquisition and recall processes in the passive avoidance test and significantly increased acute stress responses. AIDA increased locomotor activity in chHA rats (especially number of crossed fields and rearings) and produced anxiety enhancement in rats with chHA. AIDA used in rats with chHA significantly improved acquisition and retrieval processes.

CONCLUSIONS

The obtained results suggest that AIDA, the antagonist of mGluR1, had beneficial effects on learning and memory in rats with experimental chronic hyperammonemia.

Effect of MPEP on rat's behavioral activity in experimental episodes of hypoxia

PURPOSE

The influence of the selective antagonism of metabotropic glutamate receptor subtype 5 (mGluR5) by MPEP (2-methyl-6-(phenylethynyl)-pyridine) on some behaviors was tested in control groups of rats and in rats exposed to short-term hypoxia once or to repeated episodes of hypoxia.

MATERIAL AND METHODS

We used the following methods: the open field test, the passive avoidance test and the object recognition test. Experimental hypoxia was produced by placing rats in a glass chamber flushed with a mixture of 2% O2 in N2.

RESULTS

MPEP applied intravenously (IV) at the dose of 1 mg kg-1 significantly enhanced locomotor and exploratory activity, impaired acquisition, but improved consolidation and retrieval in the passive avoidance situation and did not alter rats' activity in the object recognition test. The single short-term hypoxia significantly inhibited motility of rats and profoundly impaired acquisition, consolidation and retrieval processes, but the positive effect of MPEP on retrieval was preserved. Hypoxia also did not influence the activity of rats in the object recognition object. The repeated episodes of short-term hypoxia were induced for five consecutive days and it also inhibited motility of rats, but did not change consolidation and retrieval processes. The episodes of hypoxia significantly diminished the beneficial effect of MPEP on consolidation and retrieval, and also the enhancement of locomotor and exploratory activity. MPEP, used in rats subjected to the single or the repeated episodes of short-term hypoxia, did not change recognition memory.

CONCLUSION

MPEP used before the single episode of hypoxia only, had beneficial effect on retrieval.

Metabotropic glutamate receptor ligands as potential therapeutics for addiction

There is now compelling evidence that the excitatory amino acid neurotransmitter glutamate plays a pivotal role in drug addiction and alcoholism. As a result, there has been increasing interest in developing glutamate-based therapies for the treatment of addictive disorders. Receptors for glutamate are primarily divided into two classes: ionotropic glutamate receptors (iGluRs) that mediate fast excitatory glutamate transmission, and metabotropic glutamate receptors (mGluRs), which are G-protein coupled receptors that mediate slower, modulatory glutamate transmission. Most iGluR antagonists, while showing some efficacy in animal models of addiction, exhibit serious side effects when tested in humans. mGluR ligands, on the other hand, which have been advanced to testing in clinical trials for various medical conditions, have demonstrated the ability to reduce drug reward, reinforcement, and relapse-like behaviors in animal studies. mGluR ligands that have been shown to be primarily effective are Group I (mGluR1 and mGluR5) negative allosteric modulators and Group II (mGluR2 and mGluR3) orthosteric presynaptic autoreceptor agonists. In this review, we will summarize findings from animal studies suggesting that these mGluR ligands may be of potential benefit in reducing on-going drug self-administration and may aid in the prevention of relapse. The neuroanatomical distribution of mGluR1, mGluR2/3, and mGluR5 receptors and the pharmacological properties of Group I negative allosteric modulators and Group II agonists will also be overviewed. Finally, we will discuss the current status of mGluR ligands in human clinical trials.

Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats

RATIONALE

Metabotropic glutamate 1 (mGlu1) receptor antagonists were reported to induce cognitive deficits in several animal models using aversive learning procedures.

OBJECTIVE

The present study aimed to further characterize behavioral effects of mGlu1 receptor antagonists using appetitively motivated tasks that evaluate working memory, timing, and impulsivity functions.

MATERIALS AND METHODS

Separate groups of adult male Wistar rats were trained to perform four food-reinforced operant tasks: delayed non-matching to position (DNMTP), differential reinforcement of low rates of responding 18 s (DRL 18-s), signal duration discrimination (2-s vs 8-s bisection), and tolerance to delay of reward. Before the tests, rats were pretreated with (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate (EMQMCM; 2.5-10 mg/kg, i.p.; JNJ16567083).

RESULTS

In DNMTP task, EMQMCM produced delay-dependent increases in performance accuracy so that, at 10 mg/kg dose level, percentage of correct lever choices was enhanced at 8- and 16-s delays. In DRL task, at all three tested doses, response rates were higher, and reinforcement rates were lower than under control conditions. In signal duration discrimination tasks, EMQMCM did not have any specific effects on temporal control. In tolerance to delay of reward, EMQMCM (5 and 10 mg/kg) facilitated choice of the lever associated with large reward at longer delay levels.

CONCLUSIONS

Blockade of mGlu1 receptors improves working memory and reduces impulsive choice at the doses that have no effects on time perception but appear to facilitate impulsive action.

Differential roles of hippocampal metabotropic glutamate receptors 1 and 5 in inhibitory avoidance learning

Group I metabotropic glutamate receptors (mGlu1 and 5) have been implicated in synaptic plasticity and learning and memory. However, much of our understanding of how these receptors in different brain regions contribute to distinct memory stages in different learning tasks remains incomplete. The present study investigated the effects of the mGlu5 receptor antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and mGlu1 receptor antagonist, (S)-(+)-alpha-amino-4-carboxy-2-methylbenzene-acetic acid (LY 367385) in the dorsal hippocampus on the consolidation and extinction of memory for inhibitory avoidance learning. Male, Sprague-Dawley rats were trained in a single-trial step-down inhibitory avoidance task. MPEP, LY 367385 or saline were infused bilaterally into the CA1 region immediately after training or immediately after the first retention test which was given 24h after training. Rats receiving MPEP (1.5 or 5.0 microg/side) or LY 367385 (0.7 or 2.0 microg/side) infusion exhibited a dose-dependent decrease in retention when tested 24h later. MPEP was ineffective while LY 367385 significantly attenuated extinction when injected after the first retention test using an extinction procedure. These findings indicate a selective participation of hippocampal group I mGlu receptors in memory processing in this task.

mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats

Glutamatergic neurotransmission is believed to be critically involved in the acquisition and maintenance of drug addiction. The present study evaluated the role of metabotropic glutamate (mGlu) 1 receptors in the reinstatement of nicotine-seeking behavior. Rats were trained to nose-poke to receive response-contingent intravenous infusions of nicotine (0.01 mg/kg/infusion, free base). Following the subsequent extinction phase, reinstatement tests were conducted in animals that were exposed either to response-contingent presentations of the nicotine-associated discrete light cues or to non-contingent nicotine priming injection (0.3mg/kg, s.c., salt) just prior to the test session. In a separate experiment, rats were subjected to the nearly identical response-reinstatement procedure but operant responding was established using food pellets instead of nicotine infusions. Pretreatment with the mGlu1 receptor antagonist EMQMCM (JNJ16567083, (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate) significantly inhibited cue-induced reinstatement of nicotine-seeking behavior (5 and 10, but not 2.5 mg/kg). EMQMCM (5 mg/kg) also prevented nicotine priming-induced reinstatement of nicotine-seeking behavior. At the highest tested dose only (10 mg/kg), EMQMCM attenuated cue-induced reinstatement of food-seeking behavior. Taken together with the previous reports, the present findings further suggest that blockade of mGlu1 receptors may be beneficial for preventing relapse to tobacco smoking in nicotine-dependent individuals.

Metabotropic glutamate receptor antagonist AIDA blocks induction of mossy fiber-CA3 LTP in vivo

Metabotropic glutamate receptors (mGluR) are implicated in long-term memory storage. mGluR-I and mGluR-II antagonists impede various forms of learning and long-term potentiation (LTP) in animals. Despite the evidence linking mGluR to learning mechanisms, their role in mossy fiber-CA3 long-term potentiation (LTP) is not yet clear. To explain the involvement of mGluR-I in memory mechanisms, we examined the function of the mGluR-I antagonist 1-aminoindan-1, 5-dicarboxylic acid (AIDA) on the induction of mossy fiber-CA3 LTP in vivo in male Sprague Dawley and Fischer 344 (F344) rats. Acute extracellular mossy fiber (MF) responses were evoked by stimulation of the MF bundle and recorded in the stratum lucidum of CA3. The excitatory postsynaptic potential (EPSP) magnitude was measured by using the initial slope of the field EPSP slope measured 2-3 ms after response onset. After collection of baseline MF-CA3 responses at 0.05 Hz, animals received either ((+/-))-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (N-methyl-D-aspartate-R antagonist, 10 mg/kg ip), naloxone (opioid-R antagonist, 10 mg/kg ip), or AIDA (mGluR antagonist, 1 mg/kg ip or 37.5 nmol ic). LTP was induced by two 100-Hz trains at the intensity sufficient to evoke 50% of the maximal response. Responses were collected for an additional 1 h. AIDA blocked induction of LTP in the mossy fiber pathway (P < 0.05) in both strains of rats after systemic and in Sprague Dawley rats after intrahippocampal injection.

Variation of CS salience reveals group II mGluR-dependent and -independent forms of conditioning in the rat

There is good evidence that metabotropic glutamate receptors (mGluRs) are involved in some types of learning, and we have previously suggested that this involvement may reflect the modulation by mGluRs of the signal-to-noise ratio in neural networks. This hypothesis supposes that unspecific activation of mGluRs increases background noise level, so reducing the effectiveness of behaviourally relevant stimuli as signals in the network. We report here that intraperitoneal (i.p.) injection of 4-aminopyrrolidine-2,4-dicarboxylic acid (APDC), a specific agonist of group II mGluRs, disrupts conditioning to context (but not to cue) using conventional procedures. The hypothesis predicts, however, that the effect of the drug should be counteracted by the use of more salient stimuli, which would provide stronger signals to the network. In accordance with this prediction, we find that increases in the salience of either the CS (context) or the UCS (shock) abolish the drug-induced disruption of conditioning. These results suggest that group II mGluRs modulate neural networks involved in association formation.

Involvement of mGluR(5) on acute nociceptive transmission

The effect of the mGluR(5) antagonist, MPEP (2-Methyl-6-(phenylethynyl)-pyridine), and of the mGluR(1) antagonist, AIDA((RS)-1-Aminoindan-1,5-dicarboxylic acid), were examined on nociceptive neurons in the ventroposterolateral (VPL) nucleus of the thalamus in response to pressure stimuli to the contralateral hindpaw of rats under urethane anesthesia. Intravenous (i.v.) injection of MPEP (0.1, 1, and 10 mg/kg) blocked responses to noxious stimulation in a dose-dependent and reversible manner. AIDA (3 and 15 mg/kg, i.v.), in contrast, had no effect on these cells. MPEP action was selective to noxious stimulation because even when tested at the highest dose (10 mg/kg, i.v.) it did not alter the responses of non-nociceptive neurons to brush stimulation. To investigate the site of action of MPEP, intra-thalamic injections were made during electrophysiological recordings. Using this method, the mGluR(5) antagonist did not affect nociceptive responses, suggesting that thalamic receptors were not involved in this action. On the other hand, the NMDA thalamic receptors seem to be involved because the NMDA receptor antagonist, MK801, successfully blocked responses to noxious pressure stimulation following intra-thalamic injections. In the spinal cord in vitro model, MPEP (30 microM, 60 min) was also able to attenuate ventral root potentials after single shock electrical stimulation of the dorsal root and inhibit wind-up response evoked by repetitive stimulation. Taken together, these findings suggest that blockade of the mGluR(5), but not mGluR(1) decreases nociceptive transmission in the thalamus and that these effects may be mediated by spinal cord receptors.